Insights
At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.
A tailored approach to estimate the outlook of the gene therapy market
A patient-based forecasting model was developed to estimate the outlook of the gene therapy market until 2036, using epidemiological data as a starting point. The model identified and detailed all gene therapies marketed or in development worldwide, with specific subpopulations for each asset, and assessed their impact on a given pharmaceutical national budget based on timing of the first commercial patient, probability of success, price estimates, and penetration rates. The results of the model were subject to uncertainties, but raised awareness on the necessity to be prepared to face gene therapy development and brought sustainability messages related to stakeholders in charge of public health resources.
Advanced Access for Advanced Therapies
Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.
Will Europe Miss The Boat On ATMPs?
Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access
Team Inbeeo Ready For ISPOR Europe 2022 in Vienna
Team Inbeeo is ready for ISPOR Europe 2022 in Vienna.
More than just price cuts: Improving access to essential cancer drugs in low and lower-middle-income countries
Simply making essential cancer medicines more affordable does not guarantee that patients will receive the right medicine at the right time. Whilst essential cancer medicines are almost universally available in developed markets, what is industry currently doing to facilitate access to these medicines in LLMICs, who perhaps need it most?
How should pharmaceutical companies prepare for the upcoming joint EU HTA?
The Health Technology Assessment landscape is changing in the EU – soon a single standardised assessment will be used across all member states. January 2022
Day in the life of a consultant at Inbeeo
Join Sarah, Associate Consultant at Inbeeo, as she works to solve exciting market access challenges for our global life sciences clients.
Inbeeo has been honoured with a Queen’s Award for Enterprise: International Trade
Inbeeo’s commitment to delivering stellar strategic thinking for global life sciences companies has been recognized by the top business award
France to Adopt a Market Access Pathway Like the German System
France’s Health Innovation 2030 Plan Proposes to Adopt a Market Access Pathway Like the German System to Accelerate Patient Access to Innovative Medicines – What Changes Can Be Expected?
Rare Disease Day 2021: UK Roadmap to Improving Care for Rare Disease Patients
Earlier this year, the UK government announced the Rare Diseases Framework, outlining strategy to improve the delivery of care to the 3.5 million people living within the four nations of the UK with a rare disorder.
Unpacking the biotech sector: What sets this sector apart and what are the challenges
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.
How are payers adapting to the ATMP revolution?
Our CEO Herve Lillu recently led a discussion on this topic at the 2020 World Pharma pricing, Evidence, and Market Access Congress. Before we get
Four Market Access Measures Triggered by COVID-19 That Are Here To Stay
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.
Reflections on The Initial Impact of COVID-19 on Global Market Access Activities
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
WEBINAR REPLAY – How Payers in the US & Europe are adapting to the ATMP revolution
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
Drug R&D Public Funding – The Next Level Of Price Transparency Policies?
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
Tackling Rising Drug Costs in the US: Is ERP an Option?
Rising drug prices in the US are hot topic. Inbeeo takes a look at the recent drug pricing proposal by the Democrats suggesting the use of ERP.
4 Take-Away Messages From The Zolgensma® Pricing Storm
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
Decoding the data: Analytics of Drug Pricing Tweets
Inbeeo’s analysis of 2018 drug pricing tweets using NLP machine learning techniques highlight how emotive the issue of pharmaceutical pricing really is.
Four Definitions of Value-Based Pricing and Counting
What is Value-Based Pricing? It’s pricing based on value! Or is it? Let us try to define what it is once and for all.
In France, the value equation may change (a little)
France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
Six Drugs that Cost a Medicare Part D Beneficiary more than $10,000 a Year
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
The Dust Never Settled after Drug Pricing 9/22
The event that made people pay attention to how prescription drugs are being priced
Why I Prefer a Value-Based Healthcare Mayhem over the Status Quo
The value-denial syndrome used to be broadly shared between payers and the industry, and now they both seem to come to the same realization that value-based pricing is the only way. Easier said than done, but that’s a start.
